Page last updated: 2024-11-02

pioglitazone and Adenocarcinoma, Basal Cell

pioglitazone has been researched along with Adenocarcinoma, Basal Cell in 6 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

ExcerptRelevanceReference
"In LNCaP, a human androgen-dependent prostate cancer cell line, PGZ also inhibited cyclin D1 expression and the activation of both p38 MAPK and NFκB."5.43Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis. ( Kato, H; Kobayashi, M; Kuno, T; Mori, Y; Nagano, A; Nagayasu, Y; Naiki-Ito, A; Suzuki, S; Takahashi, S, 2016)
" We investigated the biological effects of PPARgamma activation by the oral antidiabetic agent pioglitazone in Barrett's adenocarcinoma cells in vitro and in vivo."3.75Differential effects of PPARgamma activation by the oral antidiabetic agent pioglitazone in Barrett's carcinoma in vitro and in vivo. ( Al-Taie, OH; Barthelmes, HU; Graf, T; Illert, B; Katzenberger, T; Kraus, MR; Mörk, H; Scheurlen, M; Seufert, J, 2009)
" The authors analysed the effects of two TZD, rosiglitazone and pioglitazone, on invasiveness of human pancreatic carcinoma cell lines in order to evaluate the potential therapeutic use of these drugs in pancreatic adenocarcinoma."3.72Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms. ( Casini, A; Ceni, E; Crabb, DW; Galli, A; Grappone, C; Mello, T; Milani, S; Salzano, R; Surrenti, C; Surrenti, E, 2004)
"Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined."2.50Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014)
"In LNCaP, a human androgen-dependent prostate cancer cell line, PGZ also inhibited cyclin D1 expression and the activation of both p38 MAPK and NFκB."1.43Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis. ( Kato, H; Kobayashi, M; Kuno, T; Mori, Y; Nagano, A; Nagayasu, Y; Naiki-Ito, A; Suzuki, S; Takahashi, S, 2016)
"When pioglitazone was administered beginning 8 weeks after the first carcinogen treatment when microscopic adenomas already existed, pioglitazone significantly inhibited tumor load (sum of tumor volume per lung in average) by 64% (P < 0."1.36Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice. ( James, M; Lu, Y; Lubet, RA; Szabo, E; Wang, Y; Wen, W; You, M, 2010)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Herrigel, DJ1
Moss, RA1
Suzuki, S1
Mori, Y1
Nagano, A1
Naiki-Ito, A1
Kato, H1
Nagayasu, Y1
Kobayashi, M1
Kuno, T1
Takahashi, S1
Al-Taie, OH1
Graf, T1
Illert, B1
Katzenberger, T1
Mörk, H1
Kraus, MR1
Barthelmes, HU1
Scheurlen, M1
Seufert, J1
Wang, Y1
James, M1
Wen, W1
Lu, Y1
Szabo, E1
Lubet, RA1
You, M1
Li, H1
Sorenson, AL1
Poczobutt, J1
Amin, J1
Joyal, T1
Sullivan, T1
Crossno, JT1
Weiser-Evans, MC1
Nemenoff, RA1
Galli, A1
Ceni, E1
Crabb, DW1
Mello, T1
Salzano, R1
Grappone, C1
Milani, S1
Surrenti, E1
Surrenti, C1
Casini, A1

Reviews

1 review available for pioglitazone and Adenocarcinoma, Basal Cell

ArticleYear
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
    Postgraduate medicine, 2014, Volume: 126, Issue:6

    Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp

2014

Other Studies

5 other studies available for pioglitazone and Adenocarcinoma, Basal Cell

ArticleYear
Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis.
    International journal of molecular sciences, 2016, Dec-10, Volume: 17, Issue:12

    Topics: Adenocarcinoma; Animals; Body Weight; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease

2016
Differential effects of PPARgamma activation by the oral antidiabetic agent pioglitazone in Barrett's carcinoma in vitro and in vivo.
    Journal of gastroenterology, 2009, Volume: 44, Issue:9

    Topics: Adenocarcinoma; Animals; Apoptosis; Barrett Esophagus; Cell Line, Tumor; Cell Proliferation; Esophag

2009
Chemopreventive effects of pioglitazone on chemically induced lung carcinogenesis in mice.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:11

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinogens; Carcinoma, Squamous Cell; Chemopreventi

2010
Activation of PPARγ in myeloid cells promotes lung cancer progression and metastasis.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Adenocarcinoma; Animals; Bone Marrow; Coculture Techniques; Disease Progression; Fluorescent Antibod

2011
Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.
    Gut, 2004, Volume: 53, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cell Division; DNA, Neoplasm; Dose-Response Rela

2004